Wnt-5a expression in the rat neuronal progenitor cell line ST14A

Transplantation of cells derived from embryonic stem cells is currently under investigation as a promising strategy to restore functional deficits in neurodegenerative diseases, e.g. Parkinson's disease. To generate cells suitable for transplantation, a neuronal progenitor cell line (ST14A) was derived from embryonic day 14 rat striatum by stable retroviral transfection of the temperature-sensitive SV40 large T antigen and genetically modified by transfection with constructs of the neurotrophic factors ciliary neurotrophic factor (CNTF) [CNTF-ST14A] and glial cell line-derived neurotrophic factor (GDNF) [GDNF-ST14A], respectively. In order to investigate the capacity of these cells to regulate neuronal growth and physiological differentiation, e.g. remodeling of axons and synaptogenesis, we analyzed the expression of molecules which control the cell fate during embryonic development. For the first time, we found endogenous Wnt-5a, a regulator molecule that can induce dopaminergic phenotype, by RT-PCR, Western blot and flow cytometry in the neuronal progenitor cell line ST14A and its derivatives CNTF-ST14A and GDNF-ST14A. The protein was transiently upregulated at the differentiation-inducing non-permissive temperature of 39 degrees C and it was also secreted into the culture medium. Our findings are based on in vitro investigation of artificially immortalized cell lines. However, they raise the possibility that neuronal progenitor cells that might be used to treat neurodegenerative diseases express Wnt-5a, thus promoting their potential for dopaminergic differentiatio

Protocol and Methodology of the Stroke in Young Fabry Patients (sifap1) Study: A Prospective Multicenter European Study of 5,024 Young Stroke Patients Aged 18-55 Years

Background: Stroke in the young has not been thoroughly investigated with most previous studies based on a small number of patients from single centers. Furthermore, recent reports indicate that Fabry disease may be a significant cause for young stroke. The primary aim of our study was to determine the prevalence of Fabry disease in young stroke patients, while the secondary aim was to describe patterns of stroke in young patients. Methods: We initiated the Stroke in Young Fabry Patients (sifap1) study as a multinational prospective European study of stroke patients aged 18-55 years and collected a broad range of clinical, laboratory, and radiological data using stringent standardized methods. All patients were tested for Fabry disease and blood was stored for future genetic testing. Results: We managed to enroll 5,024 eligible young stroke patients in 15 countries and 47 centers across Europe between April 2007 and January 2010. The median number of patients included per center was 98 with a range between 8 and 315. The average duration of patient recruitment per center was 22 months, ranging between 5 and 33 months. The database was closed in July 2010. This paper describes protocol and methodology of the sifap1 study. Conclusion: The sifap1 study included the largest series of young stroke patients so far and will allow for analyses on a large number of aspects of stroke in the young. Copyright (C) 2010 S. Karger AG, Base